In the past week, CRBU stock has gone down by -2.53%, with a monthly decline of -1.53% and a quarterly plunge of -16.81%. The volatility ratio for the week is 8.20%, and the volatility levels for the last 30 days are 6.12% for Caribou Biosciences Inc. The simple moving average for the past 20 days is 2.06% for CRBU’s stock, with a -44.79% simple moving average for the past 200 days.
Is It Worth Investing in Caribou Biosciences Inc (NASDAQ: CRBU) Right Now?
The 36-month beta value for CRBU is at 2.27. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRBU is 79.82M, and currently, shorts hold a 14.42% of that float. The average trading volume for CRBU on October 30, 2024 was 907.87K shares.
CRBU) stock’s latest price update
The stock price of Caribou Biosciences Inc (NASDAQ: CRBU) has jumped by 2.66 compared to previous close of 1.88. Despite this, the company has seen a fall of -2.53% in its stock price over the last five trading days. seekingalpha.com reported 2024-09-30 that Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU’s chRDNA platform offers precise genome editing and could potentially outperform competitors like Allogene Therapeutics. CRBU’s flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell lymphoma, with long-term complete response rates.
Analysts’ Opinion of CRBU
Many brokerage firms have already submitted their reports for CRBU stocks, with Evercore ISI repeating the rating for CRBU by listing it as a “In-line.” The predicted price for CRBU in the upcoming period, according to Evercore ISI is $3 based on the research report published on June 03, 2024 of the current year 2024.
Evercore ISI gave a rating of “Outperform” to CRBU, setting the target price at $13 in the report published on October 31st of the previous year.
CRBU Trading at -1.86% from the 50-Day Moving Average
After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.83% of loss for the given period.
Volatility was left at 6.12%, however, over the last 30 days, the volatility rate increased by 8.20%, as shares surge +5.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.47% lower at present.
During the last 5 trading sessions, CRBU fell by -2.53%, which changed the moving average for the period of 200-days by -64.49% in comparison to the 20-day moving average, which settled at $1.8910. In addition, Caribou Biosciences Inc saw -66.32% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CRBU
Current profitability levels for the company are sitting at:
- -4.28 for the present operating margin
- 0.83 for the gross margin
The net margin for Caribou Biosciences Inc stands at -3.73. The total capital return value is set at -0.41. Equity return is now at value -42.57, with -34.17 for asset returns.
Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.4. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -46.09.
Currently, EBITDA for the company is -112.53 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 4.95. The receivables turnover for the company is 11.36for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.75.
Conclusion
In conclusion, Caribou Biosciences Inc (CRBU) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
